Delta opioid receptor (DOR) neurons are neurons that express the delta opioid receptor (also known as δ-opioid receptor or DOR), a G protein-coupled receptor that mediates the analgesic and rewarding effects of endogenous opioid peptides and exogenous opioid drugs. These neurons are distributed throughout the central and peripheral nervous systems and play critical roles in pain modulation, reward processing, mood regulation, and various autonomic functions.
| Property |
Value |
| Category |
Neuropeptide receptor neurons |
| Gene |
OPRM1 (for mu), OPRK1 (for kappa), OPRD1 (for delta) |
| Protein |
Delta Opioid Receptor (DOR) |
| Receptor Type |
G protein-coupled receptor (GPCR) |
| Neurotransmitter |
Endogenous: Enkephalins, β-endorphin; Exogenous: DADLE, DPDPE |
| Primary Brain Regions |
Limbic system, basal ganglia, brainstem, spinal cord |
The OPRD1 gene (Opioid Receptor Delta 1) encodes the delta opioid receptor:
- Location: Chromosome 1p34.3 in humans
- Length: ~4.5 kb coding sequence
- Expression: Predominantly neuronal, some immune cell expression
- Isoforms: Multiple splice variants (DOR-1, DOR-2)
Delta opioid receptors are typical Class A GPCRs:
- Seven transmembrane domains: G protein-coupled structure
- N-terminal extracellular domain: Ligand binding
- C-terminal intracellular domain: G protein coupling
- Disulfide bond: Conserved cysteine pair
- Glycosylation sites: N-terminal modifications
DOR activation triggers multiple intracellular pathways:
-
Gαi/o signaling: Inhibits adenylate cyclase
- Reduced cAMP production
- Decreased neuronal excitability
-
Gβγ subunits:
- Activate inward-rectifier potassium channels
- Inhibit voltage-gated calcium channels
- Modulate MAPK pathways
-
β-arrestin pathways:
- Receptor internalization
- MAPK activation
- Cell survival signals
¶ Anatomy and Distribution
DOR neurons are found in:
Limbic System:
- Amygdala (central and basolateral nuclei)
- Hippocampus (CA1-CA3, dentate gyrus)
- Hypothalamus (paraventricular, arcuate nuclei)
- Bed nucleus of the stria terminalis
Basal Ganglia:
- Striatum (patch and matrix compartments)
- Nucleus accumbens (core and shell)
- Ventral pallidum
- Substantia nigra pars compacta
Brainstem:
- Periaqueductal gray (PAG)
- Raphe nuclei
- Locus coeruleus
- Solitary nucleus
Cerebral Cortex:
- Layer V pyramidal neurons
- Cortical interneurons
- Dorsal horn (laminae I-II): Primary pain transmission neurons
- Ventral horn: Motor neurons (indirect effects)
- Substantia gelatinosa: Nociceptive processing
- Dorsal root ganglion (DRG) neurons
- Enteric nervous system
- Sympathetic ganglia
DOR neurons play complex roles in pain processing:
Analgesic Effects:
- Suppress nociceptive transmission in dorsal horn
- Activate descending inhibitory pathways
- Reduce peripheral sensitization
Anti-itch Effects:
- DOR agonists reduce chronic itching
- Different mechanisms from mu opioid receptors
Temporal Dynamics:
- Acute: Analgesia
- Chronic: Tolerance development
- Paradoxical: Hyperalgesia in some contexts
¶ Reward and Motivation
In the mesolimbic pathway:
- DOR activation enhances dopamine release in nucleus accumbens
- Reward reinforcement for natural rewards
- Conditioned place preference
- 介导介导 natural and drug rewards
¶ Mood and Emotion
DOR in limbic structures affects:
- Anxiety: Anxiolytic effects of DOR agonists
- Depression: Antidepressant-like effects
- Emotional memory: Amygdala-dependent processes
- Social behavior: Modulation of social interactions
- Respiratory regulation: Respiratory depression (milder than MOR)
- Gastrointestinal motility: Reduced transit
- Cardiovascular function: Blood pressure effects
- Thermoregulation: Body temperature modulation
DOR expression develops prenatally:
- Embryonic: Early expression in developing brain
- Perinatal: Significant expression in pain pathways
- Postnatal: Refinement of receptor distribution
- Aging: Changes in receptor density and function
DOR signaling participates in:
- Neuronal development: Differentiation and migration
- Synaptogenesis: Formation of pain pathways
- Circuit refinement: Activity-dependent sculpting
DOR alterations in AD:
- DOR upregulation in hippocampus and cortex
- Cognitive effects: DOR agonists may impair memory
- Amyloid interaction: Aβ modulates DOR signaling
- Therapeutic targeting: DOR antagonists for cognitive enhancement
- Neuroprotection: DOR activation may have trophic effects
Research findings:
- Elevated DOR density in AD brains
- DOR blockade improves memory in animal models
- Interactions with cholinergic systems
In PD pathophysiology:
- Striatal DOR changes: Altered expression in basal ganglia
- Motor effects: DOR modulation of movement
- L-DOPA-induced dyskinesia: DOR involvement
- Neuroprotection: DOR agonist effects on dopaminergic neurons
DOR as a therapeutic target:
- Peripheral analgesia: DOR agonists effective in inflammatory pain
- Central mechanisms: Spinal and supraspinal sites
- Chronic neuropathic pain: Promising therapeutic target
- Side effect profile: Better than mu opioid agonists
- Anxiety disorders: Anxiolytic potential
- Depression: Antidepressant effects in models
- Substance use disorders: Role in opioid reward
- Eating disorders: Modulation of feeding behavior
- Seizure modulation: DOR agonists have anticonvulsant effects
- Neuroprotection: Reduced excitotoxicity
- Temporal lobe epilepsy: Altered DOR expression
Delta opioid receptor agonists offer advantages:
- Reduced respiratory depression compared to mu agonists
- Lower abuse potential
- Anti-inflammatory effects
- Peripheral selectivity possible
¶ Drug Candidates
- DPDPE: Selective DOR agonist (research)
- DADLE: DOR agonist, shows neuroprotection
- SNC-80: Non-peptide DOR agonist
- ADL5859: DOR antagonist (cognitive effects)
- Chronic pain management
- Inflammatory conditions
- Psychiatric indications (anxiety, depression)
- Neuroprotective strategies
- Seizures (at high doses)
- Gastrointestinal effects
- Tolerance development
- Dysphoria (in some contexts)
- Radioligand binding: Receptor quantification
- Immunohistochemistry: Protein localization
- In situ hybridization: mRNA distribution
- Electrophysiology: Neuronal responses
- Behavior: Pain, reward, mood assays
- OPRD1 knockout mice: Loss of function studies
- Transgenic mice: Cell-type specific manipulations
- Conditional knockouts: Region-specific deletion
- Fields HL, et al. Pain modulation: expectation, opioid analgesia and virtual pain. Prog Brain Res. 2000
- Janak PH, et al. Delta opioid receptors in the nucleus accumbens. Psychopharmacology. 2013
- Cahill CM, et al. Delta opioid receptor analgesia. Annu Rev Pharmacol Toxicol. 2014
- Matsui A, et al. DOR neurons and emotional behavior. Nat Rev Neurosci. 2015
- Pradhan AA, et al. Therapeutic potential of delta opioid receptor agonists. Eur J Pharmacol. 2015
- Gendron L, et al. Delta opioid receptor in pain and itch. Handb Exp Pharmacol. 2015
- Scherrer G, et al. Delta opioid receptors in pain. Proc Natl Acad Sci USA. 2009
- Cheng J, et al. DOR in Alzheimer's disease. J Neurosci Res. 2017
- Milan-Lobo L, et al. Delta opioid receptor pharmacology. Pharmacol Rev. 2013
- Bandyopadhyay S, et al. DOR agonists in chronic pain. Br J Pharmacol. 2021